News >

Updated OS Data Reported With Tivozanib in Highly Refractory Metastatic RCC

Gina Columbus @ginacolumbusonc
Published: Tuesday, Sep 10, 2019

Sumanta K. Pal, MD, of City of Hope

Sumanta K. Pal, MD

Results from the second prespecified analysis of the TIVO-3 trial showed a hazard ratio for overall survival (OS) of 0.99 for tivozanib (Fotivda) compared with sorafenib (Nexavar) in patients with highly refractory metastatic renal cell carcinoma (RCC), according to AVEO Oncology, the developer of tivozanib.1
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x